http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110251473-B

Outgoing Links

Predicate Object
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4545
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2013
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2054
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2086
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-24
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4545
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-38
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-14
filingDate 2019-07-11-04:00^^<http://www.w3.org/2001/XMLSchema#date>
grantDate 2021-10-01-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationDate 2021-10-01-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber CN-110251473-B
titleOfInvention Oral slow-release preparation of oxypiperone
abstract The invention discloses an oral sustained-release preparation of oxypeperisone, which comprises the following components: hydroxypyrazine or a pharmaceutically acceptable salt thereof; one or more pharmaceutically acceptable excipients; contains at least one polymer with slow-release function. The invention selects medicinal high molecular material as slow release material, the in vitro release degree test result shows that the provided oxypiperone slow release tablet gradually releases the medicament within 8-24 hours, thereby reducing the peak valley phenomenon of medicament absorption and maintaining the blood concentration required by treatment, and compared with the common tablet, the invention can achieve the purposes of reducing the taking times, having lasting effect and convenient taking, and is more beneficial to the treatment of diseases.
priorityDate 2019-07-11-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419480019
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID426260389
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID451488935
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID1031
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID9931459
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID72758
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419507785
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID448897384
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5362585
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID450491033
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID962
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6328154
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID453754419
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID24832095
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID447990802
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID60835
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419512635
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3386
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID420241316
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID155059348
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID426080742
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID62223
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID57503849
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID24441
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419890815
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5284603
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID448546691
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419506685
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID87096726
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419501289
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID421355313
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6918314
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID50258
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID451905405

Total number of triples: 52.